Equity grants to Halozyme (NASDAQ: HALO) director Matthew Posard

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. director Matthew L. Posard received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one future share of common stock, and options for 6,040 shares at an exercise price of $65.87 per share.

The RSUs and options vest in full on the earlier of May 5, 2027 or the next annual meeting of stockholders. The RSUs are subject to a deferral election so shares are delivered when he completes his service as a director. After these grants, he directly holds 77,835 common shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Posard Matthew L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	6,040	$0.00	--
Grant/Award	Common Stock	3,796	$0.00	--

Holdings After Transaction: Option to Purchase Common Stock — 6,040 shares (Direct, null); Common Stock — 77,835 shares (Direct, null)

Footnotes (1)

1. Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Key Figures

RSU grant: 3,796 units Option grant size: 6,040 options Option exercise price: $65.87 per share +3 more

6 metrics

RSU grant 3,796 units Annual director restricted stock unit award

Option grant size 6,040 options Annual stock option grant to director

Option exercise price $65.87 per share Strike price for new options

Option expiration May 5, 2036 Expiration date of granted options

Shares after transaction 77,835 shares Common shares directly held after grants

RSU vesting date Earlier of May 5, 2027 or next meeting Full vesting trigger for RSUs and options

Key Terms

restricted stock unit ("RSU"), Directors Deferred Equity Compensation Plan, annual stock option grant, director compensation program

4 terms

restricted stock unit ("RSU") financial

"Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program."

Directors Deferred Equity Compensation Plan financial

"These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan"

annual stock option grant financial

"Represents annual stock option grant under the Issuer's director compensation program."

director compensation program financial

"Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Posard Matthew L.

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		A		3,796(1)	A	$0	77,835	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$65.87	05/05/2026		A		6,040		(2)	05/05/2036	Common Stock	6,040	$0	6,040	D

Explanation of Responses:

1. Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

2. Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Halozyme (HALO) director Matthew Posard receive?

Matthew Posard received 3,796 restricted stock units and options for 6,040 shares of Halozyme common stock. These awards are part of the company’s annual director compensation program and do not represent open-market purchases or sales of existing shares.

What is the exercise price and term of the new Halozyme (HALO) stock options?

The new stock options granted to Matthew Posard cover 6,040 shares at an exercise price of $65.87 per share. They vest in full on the earlier of May 5, 2027 or Halozyme’s next annual stockholder meeting, and expire on May 5, 2036.

How many Halozyme (HALO) shares does Matthew Posard hold after these grants?

Following the equity grants, Matthew Posard directly holds 77,835 shares of Halozyme common stock. This figure reflects his position after receiving the 3,796 restricted stock units reported in the filing, in addition to his previously held shares.

Are Matthew Posard’s Halozyme (HALO) RSUs immediately deliverable as shares?

No. The 3,796 restricted stock units are subject to a deferral election under Halozyme’s Directors Deferred Equity Compensation Plan. Shares of common stock will be released to him only upon completion of his service as a director, after vesting conditions are met.

When do Halozyme (HALO) director equity awards for Matthew Posard vest?

Both the 3,796 restricted stock units and the 6,040-share stock option grant vest in full on the earlier of May 5, 2027 or the date of Halozyme’s next annual meeting of stockholders. Vesting must occur before any shares can be delivered or options exercised.